Dr Sarathi Vin

Sarathi Bio is an early-stage biotechnology company focused on the discovery and development of next-generation precision medicines for hard-to-treat cancers. The company utilizes a specialized discovery platform to identify small molecule molecular glues that can target and degrade previously undruggable proteins, with a primary emphasis on the RAS signaling pathway. Their lead programs are centered on potent and selective inhibitors of KRAS mutations, such as KRAS G12D, which are prevalent in pancreatic, colorectal, and lung malignancies. By leveraging deep expertise in structural biology and medicinal chemistry, Sarathi Bio aims to provide transformative therapeutic options for patients with limited clinical alternatives. The company was founded by Dr. Sarathi Vin, who brings extensive experience from leadership roles at Amgen and Westlake Village BioPartners. Sarathi Bio is currently in the pre-clinical stage, advancing its pipeline toward candidate selection and IND-enabling studies.